Record mula sa primary source
Decision-gradePag-apruba ng FDA
Viatris: Inaprubahan ng FDA ang Gwyn Lo (norelgestromin/ethinyl estradiol patch)
Inaprubahan ng FDA ang Gwyn Lo, isang bagong low-dose combined hormonal contraceptive patch. Inaasahang magiging komersyal na magagamit ang produkto sa huling bahagi ng taong ito, na nagdaragdag ng bagong branded na produkto sa portfolio ng Viatris.
Mahahalagang fact
- Na-file
- Ago 6, 2026, 11:56 AM
- Kaganapan
- Pag-apruba ng FDA
- Direksyon
- Positibo
- Kumpanya
VTRSViatris- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 exhibit991-2q26earningsrel.htm EX-99.1 Document Viatris Reports Second-Quarter 2026 Financial Results • Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million • Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 • Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 • Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo TM • Announces Sale of Global Rights to Tyrvaya ® • Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x • Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH – August 6, 2026 – Viatris I